Lannett Company, Inc. announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the board will comprise eight directors. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D.